Department of Orthopaedic Surgery, Peking University China-Japan Friendship School of Clinical Medicine, Beijing 100029, China.
Department of Orthopaedic Surgery, Center for Osteonecrosis and Joint Preserving & Reconstruction, China-Japan Friendship Hospital, Beijing 100029, China.
Mediators Inflamm. 2020 Oct 26;2020:1639016. doi: 10.1155/2020/1639016. eCollection 2020.
Secukinumab is a novel IL-17A inhibitor that has been confirmed to be effective for treating PsA and RA. Several studies have demonstrated that secukinumab also provides benefits for AS patients. Thus, we performed a meta-analysis of RCTs to evaluate the short-term efficacy and safety of secukinumab for the management of AS. The PubMed, Medline, Embase, Web of Science, and Cochrane Library databases were searched for RCTs published prior to March 2020 on the treatment of AS with secukinumab. The primary outcome was the ASAS20 response, and the secondary outcomes included the ASAS40 response, ASAS5/6 response, SF-36 PCS score, ASQoL score, and AEs. Dichotomous data were expressed as pooled RRs with 95% CIs, while continuous data were expressed as pooled MDs with 95% CIs. Subgroup analysis was conducted based on whether the AS patients previously underwent treatment with TNFi. A total of 4 RCTs with 1166 patients were included in our meta-analysis. At week 16, secukinumab 150 mg yielded significant improvements in the clinical response and patient-reported outcomes for AS patients. There was no increased risk of AEs. Consistent results were detected in the meta-analysis of secukinumab 75 mg versus a placebo. Furthermore, no significant difference was detected between the secukinumab 75 mg group and secukinumab 150 mg group. We concluded that secukinumab is effective for treating AS and generally well tolerated by AS patients in the short term, regardless of whether they previously underwent TNFi treatment. The superiority of secukinumab 150 mg over secukinumab 75 mg seems to be limited, since no significant difference in any endpoint was detected between the two groups.
司库奇尤单抗是一种新型的 IL-17A 抑制剂，已被证实可有效治疗银屑病关节炎和类风湿关节炎。多项研究表明，司库奇尤单抗对强直性脊柱炎患者也有获益。因此，我们进行了一项荟萃分析，以评估司库奇尤单抗治疗强直性脊柱炎的短期疗效和安全性。检索了 PubMed、Medline、Embase、Web of Science 和 Cochrane Library 数据库，以获取截至 2020 年 3 月发表的关于司库奇尤单抗治疗强直性脊柱炎的随机对照试验。主要结局是 ASAS20 缓解，次要结局包括 ASAS40 缓解、ASAS5/6 缓解、SF-36 PCS 评分、ASQoL 评分和不良事件。二分类数据表示为汇总相对风险（RR）和 95%置信区间（CI），而连续数据表示为汇总均数差（MD）和 95%CI。根据强直性脊柱炎患者是否曾接受过 TNFi 治疗，进行了亚组分析。本荟萃分析共纳入了 4 项 RCT 研究，共 1166 例患者。在第 16 周，司库奇尤单抗 150mg 可显著改善强直性脊柱炎患者的临床缓解和患者报告的结局。不良事件的风险无增加。司库奇尤单抗 75mg 与安慰剂相比，也得出了类似的结果。此外，司库奇尤单抗 75mg 组和 150mg 组之间未发现显著差异。我们的结论是，司库奇尤单抗治疗强直性脊柱炎有效，且短期总体上可被强直性脊柱炎患者耐受，无论其是否曾接受过 TNFi 治疗。司库奇尤单抗 150mg 优于 75mg 的优势似乎有限，因为两组之间在任何终点均未发现显著差异。
